|
|
 |
|
Viewing report
|
|
|
|
Acorda Therapeutics, Inc. - Strategy and SWOT Report
MarketLine, Nov 2011, Pages: 48
Acorda Therapeutics, Inc. - Strategy and SWOT Report, is a source of comprehensive company data and information. The report covers the company’s structure, operation, SWOT analysis, product and service offerings and corporate actions, providing a 360° view of the company.
Features:
- Detailed information on Acorda Therapeutics, Inc. required for business and competitor intelligence needs
- A study of the major internal and external factors affecting Acorda Therapeutics, Inc. in the form of a SWOT analysis
- An in-depth view of the business model of Acorda Therapeutics, Inc. including a breakdown and examination of key business segments
- Intelligence on Acorda Therapeutics, Inc.’s mergers and acquisitions (M&A), strategic partnerships and alliances, capital raising, private equity transactions, and financial and legal advisors
- News about Acorda Therapeutics, Inc., such as business expansion, restructuring, and contract wins
- Large number of easy-to-grasp charts and graphs that present important data and key trends
Highlights:
Acorda Therapeutics (Acorda) is a commercial-stage biotechnology company engaged in the development and marketing of therapies to restore function in persons with spinal cord injury (SCI), multiple sclerosis (MS) and related conditions of the central nervous system (CNS). Acorda's marketed products include Ampyra (dalfampridine), Zanaflex Capsules (tizanidine hydrochloride) and Zanaflex (tizanidine hydrochloride) tablets. The company primarily operates in the US. It is headquartered in Hawthorne, New York, and employed 305 people as of February 17, 2011. The company recorded total net revenues of $191 million during the financial year (FY) ended December 2010, as compared to the revenues of $54.7 million in FY2009. The operating loss of the company was $8.4 million during FY2010, as compared to an operating loss of $81.3 million in FY2009. The net loss was $11.8 million in FY2010, as compared to a net loss of $83.9 million in FY2009.
Reasons to Purchase:
- Gain understanding of Acorda Therapeutics, Inc. and the factors that influence its strategies
- Track strategic initiatives of the company and latest corporate news and actions
- Assess Acorda Therapeutics, Inc. as a prospective partner, vendor or supplier
- Support sales activities by understanding your customers' businesses better
- Stay up to date on Acorda Therapeutics, Inc.’s business structure, strategy and prospects
|
|
|
|
